- DIPHENYLBUTYPIPERIDINE AUTOPHAGY INDUCERS
-
Autophagy inducing compounds, methods of their preparation and use, and kits containg said compounds are disclosed herein.
- -
-
Page/Page column 7; 87-90
(2011/12/02)
-
- Phenylamino-substituted piperidine compounds, their preparation and use as medicaments
-
The present invention relates to phenylamino-substituted piperidine compounds of general formula (I), methods for their preparation, medicaments comprising these compounds as well as their use for the preparation of a medicament for the treatment of human
- -
-
Page/Page column 29
(2008/12/04)
-
- Piperidine amides as 11β-hydroxysteroid dehydrogenase type 1 inhibitors
-
A series of piperidine amide inhibitors of human 11β-hydroxysteroid dehydrogenase type 1 (11β-HSD1) were identified via modifications of the HTS hit compound 1. The synthesis, in vitro biological evaluation, and structure-activity relationship of these co
- Flyrén, Katarina,Bergquist, Lars O.,Castro, Victor M.,Fotsch, Christopher,Johansson, Lars,St. Jean Jr., David J.,Sutin, Lori,Williams, Meredith
-
p. 3421 - 3425
(2008/02/08)
-
- Method for treating allergies using substituted pyrazoles
-
A method for treating an allergic condition, including an atopic allergic condition, using substituted pyrazoles.
- -
-
-
- Phenoxyalkylamine derivatives useful as opioid receptor agonists
-
A medicament useful for preventive and/or therapeutic treatment of nerve system diseases which comprises, as an active ingredient, a compound represented by the following general formula (I) or a pharmacologically acceptable salt thereof: wherein, X represents a group represented by the following general formula (II), (III), (IV), (V), or (VI), “A” represents a saturated or unsaturated 3- to 6-membered carbocyclic group and the like, “B” represents CH2 and the like, “n” represents 0 to 2, R1 represents a hydrogen atom, a halogen atom and the like, R2, R3, and R7 to R14 represent a hydrogen atom, a lower alkyl group which may be substituted and the like, R4 represents a hydrogen atom, a lower alkyl group which may be substituted and the like, R5 represents a hydrogen atom, a halogen atom and the like, R6 represents a saturated or unsaturated monocyclic or bicyclic carbocyclic group and the like, and R5 and R6, R7 and R8, R9 and R10, or R11 and R12 may bind to each other to form a cyclic structure.
- -
-
-
- alpha 1a adrenergic receptor antagonists
-
This invention relates to novel compounds, their synthesis and use as selective alpha 1a adrenergic receptor antagonists. One application of the compounds is in the treatment of benign prostatic hyperplasia. The compounds are selective in their ability to relax smooth muscle tissue enriched in the alpha 1a receptor subtype without at the same time inducing hypotension. One such tissue is found surrounding the urethral lining. Therefore, one utility of the instant compounds is to provide acute relief to males suffering from benign prostatic hyperplasia, by permitting less hindered urine flow. Another utility of the instant compounds is provided by combination with a human 5-alpha reductase inhibitory compound, such that both acute and chronic relief from the effects of benign prostatic hyperplasia are achieved.
- -
-
-
- Alpha 1a adrenergic receptor antagonists
-
This invention relates to novel compounds, their synthesis and use as selective α 1a adrenergic receptor antagonists. One application of the compounds is in the treatment of benign prostatic hyperplasia. The compounds are selective in their ability to relax smooth muscle tissue enriched in the α 1a receptor subtype without at the same time inducing hypotension. One such tissue is found surrounding the urethral lining. Therefore, one utility of the instant compounds is to provide acute relief to males suffering from benign prostatic hyperplasia, by permitting less hindered urine flow. Another utility of the instant compounds is provided by combination with a human 5-alpha reductase inhibitory compound, such that both acute and chronic relief from the effects of benign prostatic hyperplasia are achieved.
- -
-
-
- INHIBITORS OF FARNESYL-PROTEIN TRANSFERASE
-
The present invention is directed to compounds which inhibit farnesyl-protein transferase (FTase) and the farnesylation of the oncogene protein Ras. The invention is further directed to chemotherapeutic compositions containing the compounds of this invention and methods for inhibiting farnesyl-protein transferase and the farnesylation of the oncogene protein Ras
- -
-
-
- Design and synthesis of N-alkylated saccharins as selective α-1a adrenergic receptor antagonists
-
Benign prostatic hyperplasia can be managed pharmacologically with α-1 adrenergic receptor antagonists. Agents that demonstrate selectivity for the α-la receptor subtype may offer advantages in clinical applications with respect to hypotensive side effect
- Nerenberg, Jennie B.,Erb, Jill M.,Thompson, Wayne J.,Lee, Hee-Yoon,Guare, James P.,Munson, Peter M.,Bergman, Jeffrey M.,Huff, Joel R.,Broten, Theodore P.,Chang, Raymond S. L.,Chen, Tsing B.,O'Malley, Stacey,Schorn, Terry W.,Scott, Ann L.
-
p. 2467 - 2472
(2007/10/03)
-